About
Acceptance rate:
17%
Time to first decision with review:
27 days*
Acceptance to publication:
9 days*
Impact Factor (JCR):
19.103
Impact Factor rank (JCR):
2/34
Citescore:
28.5
Aims and Scope
Annals of the Rheumatic Diseases (ARD) is an international peer review journal committed to promoting the highest standards of scientific exchange and education. It covers all aspects of rheumatology, which includes the spectrum of musculoskeletal conditions, arthritic disease, and connective tissue disorders. ARD publishes basic, clinical, and translational scientific research.
Annals of the Rheumatic Diseases is the flagship of BMJ’s rheumatology portfolio and has two companion journals: RMD Open for original research in rheumatology and musculoskeletal disorders and Lupus Science & Medicine for original research in lupus and related diseases.
For information about the Annals of the Rheumatic Diseases Editor-in-Chief Prof Josef Smolen and his editorial team, please refer to the Editorial Board page.
Plan S compliance
Annals of the Rheumatic Diseases is a Plan S compliant Transformative Journal. Transformative Journals are one of the compliance routes offered by cOAlition S funders, such as Wellcome, WHO and UKRI. Find out more about Transformative Journals and Plan S compliance on our Author Hub.
Journal Information
Ownership
ARD is co-owned by the European Alliance of Associations for Rheumatology (EULAR) and BMJ
Publication Model
Subscription; with hybrid open access option
Frequency
Monthly
Launch date
1939
Indexed by
Web of Science Core Collection: Science Citation Index, Science Citation Index Expanded; BIOSIS Previews, Current Contents: Clinical Medicine, Life Sciences; MEDLINE (Index Medica), PubMed Central (BMJ Open Access Special Collection), Scopus, Embase (Excerpta Medica), CINAHL, Google Scholar
Peer Review Model
Single blind; the names of reviewers are hidden from the author
Print ISSN
0003-4967
Online ISSN
1468-2060
Journal Statistics (2021)
Acceptance rate: 17%
Speed
Time to first decision without review (median): 2 days
Time to first decision with review (median): 27 days
Time from acceptance to publication (median): 9 days
Impact
Impact Factor category: Rheumatology
Impact Factor (JCR): 27.973
Impact Factor rank: 3/34
5 Year Impact Factor: 20.778
Journal Citation Indicator (JCI): 4.33
Eigenfactor: 0.06152
Citescore: 28.5
Citescore rank: 1/60
Scimago Journal rank (SJR): 5.366
Reach
2021 total content views: 2,436,633
2021 total Altmetric mentions: 108,77
The impact that academic research has cannot be defined by one single metric. In 2013, BMJ signed the San Francisco Declaration on Research Assessment (DORA). We did this to show our support for using multiple measures and metrics to portray journals’ impact; moving away from the Impact Factor as a single measure.
How we get these metrics
Contact Information
For all contact information please refer to the Contact Us page.
For Authors
Please refer to the Instructions for Authors.
Subscriptions
Rights and Permissions
Affiliations
ARD is the official journal of European Alliance of Associations for Rheumatology (EULAR) and all (scientific) delegates to the annual EULAR congress receive a complimentary 12 month subscription to the journal.
BMJ is a founding member of COPE (the Committee on Publication Ethics), which provides a forum for publishers and Editors of scientific journals to discuss issues relating to the integrity of the work submitted to or published in their journals.
The EQUATOR Network is an international initiative that seeks to improve the value of medical research literature by promoting transparent, accurate reporting of research studies. BMJ is a sponsor of its activities.
BMJ is a founding organisation of the AllTrials initiative, which calls for all past and present clinical trials to be registered and their results reported.